Phase 1 Study of C.001 for Retinal Degeneration
This is a Phase 1 study testing the safety of a new treatment called C.001 for people with certain retinal diseases, like Geographic Atrophy or Stargardt Disease. These conditions involve the degeneration of the retinal pigment epithelium (RPE), a layer of cells in the eye. You would receive a single injection of C.001 directly into your eye (subretinal injection). Researchers want to see if C.001 is safe over 3 months, and they will also watch for changes in your vision and eye structure for up to 12 months. This study is for adults aged 18 and older who meet specific vision and health requirements. The current recruitment status is unclear.
- Study design
- This is a Phase 1, single-center, open-label study with 15 planned participants. It will test three different dose levels of C.001 sequentially.
- What's involved
- You would receive a single subretinal injection of C.001. You will have follow-up visits for safety assessments for up to 12 months.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for up to 12 months after treatment to assess safety and explore changes in vision and eye structure.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Phase 1 Study of C.001 in Retinal Degeneration
At a glance
Conditions
Where it's being run
3 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Incidence of Ocular and Systemic Adverse Events3 months